This in silico investigation fundamentally reshapes the search for AD therapeutics, unveiling a potent new class of multitarget ligand candidates through systematic evaluation against four critical AD proteins: sortilin, clusterin, tau, and amyloid. This evidence concerns the gene SORT1 and Alzheimer disease.